AION Labs

Last updated
AION Labs
Company typeVenture Studio
IndustryAI, Machine Learning, Pharmaceutical Discovery, Drug Development
Founded2021;3 years ago (2021)
Key people
Mati Gill (CEO), Yair Benita (CTO)
Website aionlabs.com

AION Labs is an Israeli [1] venture studio focused on the adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical discovery and development processes. [2] [3] [1] [4]

Contents

It is backed by eight major companies in the pharmaceutical, technology, and investing sectors. [5] [6] [7] This partnership includes pharmaceutical companies AstraZeneca, [8] Merck KGaA, [9] Pfizer, [10] and Teva Pharmaceuticals; [11] venture capital firms Israel Biotech Fund [12] and Amiti Ventures; [13] strategic partner Amazon Web Services; [14] and independent research institute BioMed X, [15] with support from the Israel Innovation Authority. [16]

History

AION Labs was formed after winning a government tender in 2020, bringing together AstraZeneca, Merck KGaA, Pfizer, and Teva—from the pharmaceutical sector—with Amazon Web Services (AWS), a technology and cloud computing provider, and biotech and deeptech VC firms Israel Biotech Fund and Amiti Ventures. The Management team of the company includes CEO Mati Gill [17] [18] and CTO Yair Benita. [19]

In 2022 and 2023, it was nominated for the Prix Galien USA Award for its work in AI and healthcare [20] and awarded "Most Valuable Collaboration Award" by Reuters Pharma Awards USA 2022. [21]

In February 2023, AION Labs introduced DenovAI, a venture focused on antibody discovery through an AI-powered computational platform. DenovAI's technology is designed to discover antibodies de novo, expediting and economizing the process. [22] [23]

In January 2024, AION Labs unveiled TenAces Biosciences, [24] [25] a venture in the field of molecular glue discovery using machine learning. Formed from AION Labs' initiative to develop AI platforms for targeted protein degradation, TenAces focuses on accelerating the discovery and development of new molecular glue therapies. [26]

In February 2024, the challenge of developing an AI/ML platform for Targeting RNA with Small Molecules was launched via a Call for Applications. [27]

In March 2024, it launched CombinAble.AI, a startup resulting from an AION Labs' startup challenge aimed at the antibody design process. [28] [29]

Activities

AION Labs focuses on developing AI and computational technologies in drug discovery and development in the pharmaceutical industry. It aids in the creation of companies in the pharmaceutical sector. The studio’s venture creation model leverages the BioMed X model and focuses on: [30]

Companies

DenovAI

DenovAI focuses on expediting drug discovery by creating an AI-based platform designed to generate high-affinity therapeutic antibodies and miniprotein binders for specific protein targets from scratch. [22]

TenAces

TenAces Biosciences is focused on advancing the development of molecular glue therapeutics designed for targeted protein degradation. Employing a data-centric approach and machine learning, TenAces explores protein interactions, pairs, and multi-dimensional features to predict new molecular glues to enhance therapeutic outcomes. [33] [25]

Combinable.AI

Combinable.AI focuses on addressing challenges in pharmaceutical development and manufacturing by developing an in silico method for optimizing antibody properties simultaneously. This approach aims to speed up the drug discovery process by identifying multiple candidates that achieve a balanced profile across diverse characteristics, reducing the reliance on trial-and-error methods. [34] [35]

Omec.AI

Omec.AI focuses on improving the likelihood of success for drug candidates in clinical trials through the analysis of pre-clinical safety and efficacy data. The platform builds computational models to detect potential safety concerns and efficacy issues early in the drug development process. [36]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

Christoph Westphal is an American biomedical businessman.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

<span class="mw-page-title-main">Santaris Pharma</span> Biopharmaceutical company founded in Denmark

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

<span class="mw-page-title-main">SOM Biotech</span>

SOM Innovation Biotech, S.A., is a private pharmaceutical company focused on the accelerated discovery and development of therapies for orphan diseases through a proprietary artificial intelligence-based drug discovery technology and developing strategic partnerships with major research centers and pharmaceutical companies. The company was founded in 2009 in Barcelona, Spain.

Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development.

<span class="mw-page-title-main">Scientist.com (company)</span> Network of e-commerce marketplaces

Scientist.com is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services. The company was founded in 2007 by Kevin Lustig, Chris Petersen and Andrew Martin and launched its first public research marketplace in September 2008.

<span class="mw-page-title-main">Kevin Lustig</span>

Kevin Donald Lustig is an American scientist and entrepreneur and founder of three life science companies: the pharmaceutical company Kalypsys in 2001; the online research marketplace Scientist.com in 2007; and the non-profit lab incubator Bio, Tech and Beyond in 2013.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

<span class="mw-page-title-main">Gregory L. Verdine</span> American chemical biologist

Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

Owkin is an AI biotech company that uses artificial intelligence to identify new treatments, optimize clinical trials and develop AI diagnostics. The company uses federated learning, a type of privacy preserving technology, to access multimodal patient data from academic institutions and hospitals to train its AI models for drug discovery, development, and diagnostics. Owkin has collaborated with pharmaceutical companies around the world to improve their therapeutic programs.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that focuses on mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering.

References

  1. 1 2 Spiro, James (2024-01-08). "Amiti Ventures joins pharma venture studio AION Labs as a Strategic Partner". ctech. Retrieved 2024-07-12.
  2. ↑ "Executive Conversations: Using AI and ML to accelerate joint learning in pharmaceuticals with consortium members of AION Labs | AWS for Industries". aws.amazon.com. 2022-12-13. Retrieved 2024-07-12.
  3. ↑ Wrobel, Sharon (28 February 2023). "Israel lab backed by pharma giants mints startup for computer-designed antibodies". timesofisrael.com. Retrieved 2024-07-12.
  4. ↑ Jaffe-Hoffman, Maayan (2024-03-17). "Israeli startup to use AI to transform antibody discovery, design". The Jerusalem Post | JPost.com. Retrieved 2024-07-12.
  5. ↑ Vinluan, Frank (2021-10-17). "Four big pharma companies team up in AI initiative focused on drug R&D". MedCity News. Retrieved 2024-07-12.
  6. ↑ "AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab". PharmTech. 2021-10-14. Retrieved 2024-07-12.
  7. ↑ Miller, Sara (2024-04-01). "In Israel, Big Pharma & Innovators Are Using Tech To Fight Disease". NoCamels. Retrieved 2024-07-12.
  8. ↑ "Data Science & Artificial Intelligence: Unlocking new science insights". www.astrazeneca.com. Retrieved 2024-07-12.
  9. ↑ "Scope of Consolidation. List of shareholdings". merckgroup.com. Retrieved 2024-07-12.
  10. ↑ "Partnering News | Pfizer". www.pfizer.com. Retrieved 2024-07-12.
  11. ↑ "Revolutionary Innovations in Medicine Propelled by AI and Cross-Industry Collaboration". www.tevapharm.com. August 3, 2023. Retrieved 2024-07-12.
  12. ↑ "Israel Biotech Fund – Israel Biotech Fund". 2024-07-04. Retrieved 2024-07-12.
  13. ↑ "Amiti Blog - Amiti Ventures joins pharma venture studio AION Labs as a Strategic Partner". www.amiti.vc. Retrieved 2024-07-12.
  14. ↑ "AWS joins pharma and biotech leaders in launching AION Labs to transform therapeutics | AWS for Industries". aws.amazon.com. 2021-10-13. Retrieved 2024-07-12.
  15. ↑ "AION Labs". BioMed X Institute. Retrieved 2024-07-12.
  16. ↑ "Innovation Labs List". רשות החדשנות (in Hebrew). Retrieved 2024-07-12.
  17. ↑ "The Israel-America Chamber of Commerce - Mati Gill". www.amcham.co.il. Retrieved 2024-07-12.
  18. ↑ "Mati Gill". Healthcare Technological Innovation Program - Lahav. Retrieved 2024-07-12.
  19. ↑ Ben-David, Ricky (14 October 2021). "New innovation lab brings together pharma, biotech giants for AI therapeutics". timesofisrael.com. Retrieved 2024-07-12.
  20. ↑ Lovegrove, Gemma (2022-08-18). "Prix Galien USA award nominees announced". AIMed. Retrieved 2024-07-12.
  21. ↑ "Pharma Awards USA 2024". events.reutersevents.com. Retrieved 2024-07-12.
  22. 1 2 "AION Labs launches second startup focused on AI-enabled antibody design". MobiHealthNews. 2023-02-28. Retrieved 2024-07-12.
  23. ↑ Blizovsky, Avi (March 4, 2023). "AION Labs is establishing the startup DenovAI that will deal with the design of antibodies and drugs". hayadan.com. Retrieved 2024-07-12.
  24. ↑ Goldberg, Niva (2024-01-31). "Israel's Aion Labs Establishes TenAces to Develop New Molecular Glue Therapies" . Retrieved 2024-07-12.
  25. 1 2 Jaffe-Hoffman, Maayan (2024-02-03). "AION Labs unveils TenAces start-up, will use AI to predict molecular glues". The Jerusalem Post | JPost.com. Retrieved 2024-07-12.
  26. ↑ Sohail, Syed Hamza (2024-01-30). "Molecular Glue Revolution: TenAces Biosciences Unveils AI-Powered Drug Discovery Platform". hitconsultant.net. Retrieved 2024-07-12.
  27. ↑ "התוכנית הזאת הופכת רעיונות לסטארטאפ – מהמחקר ועד גיוס משקיעים" [This program turns ideas into startups - from research to recruiting investors]. geektime.co.il (in Hebrew). Retrieved 2024-07-12.
  28. ↑ "סטארט-אפ בינה מלאכותית חדש בישראל: זה התחום בו יעסוק". Ice (in Hebrew). 2024-03-12. Retrieved 2024-07-12.
  29. ↑ "AION Labs launches CombinAble.AI to design antibodies for therapeutic development". MobiHealthNews. 2024-03-15. Retrieved 2024-07-12.
  30. ↑ "BioMed X: Tackling the unmet need in biomedical research & development | Business & Corporate News". 2020-04-20. Retrieved 2024-07-12.
  31. ↑ "ICDK Tel Aviv attracting multinational companies to the innovation ecosystem Best practices from Israel". icdk.dk. ISBN   978-87-94128-61-2 . Retrieved 2024-07-12.
  32. ↑ Jaffe-Hoffman, Maayan (2021-10-19). "Pfizer, AstraZeneca help launch 'computational science' lab in Israel". The Jerusalem Post | JPost.com. Retrieved 2024-07-12.
  33. ↑ וינרב, גלי (2024-02-11). "המוצר הישראלי שהקפיץ את מניית התרופות האמריקאית ב-42%". Globes. Retrieved 2024-07-12.
  34. ↑ Dargan, James (2024-03-21). "AION Labs Unveils CombinAble.AI, Aimed at Crafting Antibodies for Therapeutics, Following Its Fifth Startup Challenge in Israel". AI Insider. Retrieved 2024-07-12.
  35. ↑ "AION Labs Launches CombinAble". 2024-03-19. Retrieved 2024-07-12.
  36. ↑ McNamee, Aidan (2023-05-30). "AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery". Pharmaceutical Technology. Retrieved 2024-07-12.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.